Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2019 Apr 1;54(12):2117–2119. doi: 10.1038/s41409-019-0507-3

Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)

Paul Richardson 1, Saurabh Aggarwal 2,✉, Ozlem Topaloglu 2, Kathleen F Villa 3, Selim Corbacioglu 4
PMCID: PMC7608333  PMID: 30932018

Correction to:Bone Marrow Transplantation

10.1038/s41409-019-0474-8

published online 25 Feb 2019

The original version of this article included some minor typesetting errors in Table 1–a corrected version of which is provided in this correction article and has been corrected in the original article–and one error in text, which has been corrected in the original article. Furthermore, the article was erroneously published with the copyright holders as ‘Springer Nature Limited’, however, since the article is Open Access, the copyright holders should in fact be ‘The Author(s)’. This has also been corrected in the original article.

Table 1.

Summary of report characteristics, patient demographics, transplant type, and disease parameters

Study quality factors Defibrotide-treated Age Transplant Common underlying diseases
Reference* Prospective? Type Control Total MOD No MOD Median  ≤ 16 years  > 16 years Auto Allo ALL AML Other
Richardson 1998 [1] Yes Single center No 19 19 0 40 3 16 11 8 1 3 15
Chopra 2000 [2] Yes CU No 40 26 14 30 11 29 14 26 6 14 20
Richardson 2002 [3] Yes CU No 88 88 0 35 29a 59a 28 60 6 22 60
Corbacioglu 2004 [4] No CU No 45 22 23 8.2 40 5 8 37 6 10 29
Bulley 2007 [5] No Single center No 14 NR NR 10.2 14b 0b 0 14 3 1 10
Sucak 2007 [6] No Single center No 14 6 8 40.5 0b 14b 1 13 4 5 5
Richardson 2010 [7] Yes Phase 2, dose finding No 149 149 0 34 48a 101a 20 129 15 47 87
Ruiz Ramos 2014 [8] No Observational No 11 NR NR NR 4 5 NR NR NR NR NR
Locatelli 2015 [9] Yes CU No 98 17 77 13.4 52a 42a 10 75 18 23 57
Triplett 2015 [10] Yes Single center No 34 22 12 8.9 31a 3a 2 29 10 10 14
Balade Martinez 2016 [11] No Observational No 42 42 0 46 12 30 NR NR NR NR NR
Corbacioglu 2016 [12] Yes CU No 710 261 348 25 303a 407a 112 499 120 177 413
Pol 2016 [13] No Single center No 13 12 1 60.5 0 13 0 13 0 7 6
Richardson 2016 [14] Yes Phase 3 Historical 102 102 0 21 44 58 12 90 17 29 56
Strouse 2016 [15] No Registry Not treated 41 41 0 11 25 (61) 16 (39) 2 (5) 39 (95) 19c 22
Yakushijin 2016 [16] No Registry Thrombo-modulin 24 NR NR 40 NR NR 0 65 NR NR NR
Richardson 2017 (T-IND) [17] Yes T-IND No 1154 571 NR 12 691 463 155 843 279 279 596
Open in a new tab

ALL, acute lymphocytic leukemia; Allo, allogeneic; AML, acute myelogenous leukemia; Auto, autologous; CU, compassionate use; MOD, multi-organ dysfunction; NR, not reported; T-IND, defibrotide expanded access program

aPediatric defined as ≤ 18 years and adults as > 18 years

bInclusive of age 16 years

cAcute leukemias

*These references are listed in accordance with the correction article, however in the original article the reference numbers differ, as they are in accordance with the original article

References

  • 1.Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–44. [PubMed] [Google Scholar]
  • 2.Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122–9. doi: 10.1046/j.1365-2141.2000.02475.x. [DOI] [PubMed] [Google Scholar]
  • 3.Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–43. doi: 10.1182/blood-2002-04-1216. [DOI] [PubMed] [Google Scholar]
  • 4.Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189–95. doi: 10.1038/sj.bmt.1704329. [DOI] [PubMed] [Google Scholar]
  • 5.Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer. 2007;48:700–4. doi: 10.1002/pbc.20934. [DOI] [PubMed] [Google Scholar]
  • 6.Sucak GT, Aki ZS, Yagcí M, Yegin ZA, Ozkurt ZN, Haznedar R. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant Proc. 2007;39:1558–63. doi: 10.1016/j.transproceed.2007.01.075. [DOI] [PubMed] [Google Scholar]
  • 7.Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16:1005–17. doi: 10.1016/j.bbmt.2010.02.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ruiz Ramos J, Company Albir MJ, Favieres Puigcerver C, Marrero Álvarez P, Megias Vericat JE, Valero García S, et al. CP-129 Defibrotide for sinusoidal obstruction syndrome: a single centre experience. Eur J Hosp Pharm. 2014;21:A52. doi: 10.1136/ejhpharm-2013-000436.127. [DOI] [Google Scholar]
  • 9.Locatelli F, Faraci M, Cesaro S, Pagliara D, Fagioli F, Zecca Marco, et al. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following hematopoietic stem cell transplantation or chemotherapy―results from the Italian Therapeutic Use Protocol. Blood. 2015;126:3107. doi: 10.1182/blood.V126.23.3107.3107. [DOI] [Google Scholar]
  • 10.Triplett BM, Kuttab HI, Kang G, Leung W. Escalation to high-dose defibrotide in patients with hepatic veno-occlusive disease. Biol Blood Marrow Transplant. 2015;21:2148–53. doi: 10.1016/j.bbmt.2015.08.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Balade Martinez L, Valle LGD, Martin ER, De Sebastian Rueda M, Molia Cabezuelo M, Herrero Ambrosio A. CP-062 Defibrotide for the treatment of severe hepatic veno-occlusive disease. A single centre experience. Eur J Hosp Pharm. 2016;23:A27–A28. doi: 10.1136/ejhpharm-2018-001575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program. Biol Blood Marrow Transplant. 2016;22:1874–82. doi: 10.1016/j.bbmt.2016.07.001. [DOI] [PubMed] [Google Scholar]
  • 13.Pol RR, Russell N, Das-Gupta E, Watson L, Rachael L, Byrne J. Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide. Bone Marrow Transplant. 2016;51:1262–4. doi: 10.1038/bmt.2016.99. [DOI] [PubMed] [Google Scholar]
  • 14.Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656–65. doi: 10.1182/blood-2015-10-676924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, et al. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016;22:1306–12. doi: 10.1016/j.bbmt.2016.04.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Yakushijin K, Ikezoe T, Ohwade C, Kudo K, Okamura H, Goto H, et al. Nationwide survey of defibrotide and recombinant human soluble thrombomodulin for treatment of sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:S77–S78. doi: 10.1038/bmt.2015.283. [DOI] [Google Scholar]
  • 17.Richardson P, Smith A, Triplett B, Kernan N, Grupp S, Antin J, et al. Final efficacy and safety results from a defibrotide expanded-access program for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Bone Marrow Transplant. 2017;52:S64–S65. [Google Scholar]

Articles from Bone Marrow Transplantation are provided here courtesy of Nature Publishing Group

RESOURCES